1.
Pathol Biol (Paris)
; 60(4): 229-33, 2012 Aug.
Article
in French
| MEDLINE
| ID: mdl-22743095
ABSTRACT
The tyrosine kinase inhibitors (TKI) are small molecules of low molecular weight that inhibit tyrosine kinases, enzymes responsible for the activation of signal transduction cascades. Currently, a number of TKI received approval in various cancers, while others are in clinical development process: TKI are specifically clinically active when they target a tyrosine kinase (TK) with constitutional activity subsequent to a mutation, being then a master-gene driving transformation and tumour progression. Already, this drug-family provides a major therapeutic weapon against cancer.
Subject(s)
Antineoplastic Agents/therapeutic use , Neoplasms/drug therapy , Protein Kinase Inhibitors/therapeutic use , Protein-Tyrosine Kinases/antagonists & inhibitors , Benzamides , Humans , Imatinib Mesylate , Molecular Targeted Therapy , Piperazines/therapeutic use , Protein Kinase Inhibitors/pharmacokinetics , Pyrimidines/therapeutic use , Signal Transduction/drug effects
2.
Mali Med
; 25(4): 57-8, 2010.
Article
in French
| MEDLINE
| ID: mdl-21470955